You are on page 1of 12

How to improve patient’s safety without disrupting ongoing care processes

© 2008 TASC Management / Tech4Care T/TfC 06221

 In the Netherlands it is mandatory that every hospital and
medical treatment facility has a Safety Management System in
 Many medical facilities focus on introducing procedural and
sometimes very process disrupting safety systems
 TASC Management, in close cooperation with Jeroen Bosch
Medical Center and SIMAC Quadcore has developed a
practical product which improves the safety of riskful
processes significantly, without changes in ongoing processes.

© 2008 TASC Management / Tech4Care T/TfC 06222

Product effectiveness
 Structural reduction of defined risks of a specific treatment
process in healtcare
 Structural increase of the patient’s safety experience during
riskful treatment
 Significant reduction of the administrative effort of nurses and
medical staff by automatic logging of process data

 These effects will be achieved by the use of RFID technology

to support high risk healthcare processes

© 2008 TASC / Tech4Care Intro sheet # TfC/07/020003

Implementation process
 The implementation of Tech4Care® consists of 7 phases:
 Phase 1: introduction and analysis of the process to be covered
by the product
 Phase 2: risk analysis through (H)FMEA
 Phase 3: follow up (H)FMEA outcome and definition of
activities to be covered by Tech4Care®
 Phase 4: Choice of right RFID technology
 Phase 5: Implementation and instruction of key users
 Phase 6: Evaluation
 Phase 7: Transfer to production

© 2008 TASC / Tech4Care Intro sheet # TfC/07/020004

Tech4Care® as a product
 The Tech4Care® product has been developed in cooperation
with the Jeroen Bosch (JBZ) Medical Center at
Den Bosch, Netherlands
 Since Fall 2007 the product is being used for the treatment of
cancer patients with cythostatics
 Cythostatics are drugs which are being produced by the local
hospital pharmacy
 Use of cythostatics is very critical:
 Every patient has a specific prescription (dose, order of
use, prevention of side effects)
 Once produced cythostatic needs to be used within the
next 12-24 hours

© 2008 TASC / Tech4Care Intro sheet # TfC/07/020005

The use of Tech4Care®
 The product covers the cycle from the point where the doctor
has defined the prescription for a specific patient to the end
of the treatment of the patient in the hospital’s ward.
 Production of the prescribed drugs (cythostatic), transport of
the drugs, authentication of the patient, programming of the
infuse and additional incidents are inclusive.

© 2008 TASC / Tech4Care Intro sheet # TfC/07/020006

Outlines of the Tech4Care® workflow
Nursing Approval
End of
Scheduling Treatment
Diagnosis Recipe

Transport Transport

of drug



© 2008 TASC / Tech4Care Intro sheet # TfC/07/020007
RFID technology and Tech4Care®

Acceptance/ Reception
Production Transport Treatment
Approval Pharmacy

Reader Reader Reader Reader Reader

Printer Reader

•RFID Reader: partly fixed and partly

handheld -> treatment
Pharmacist •Readers work ‘online’; they have a
on duty continuous link with the central
database that contains all necessary Server
data of patients, medication and
Reader treatment

© 2008 TASC / Tech4Care Intro sheet # TfC/07/020008

Basic Tech4Care® Process lay out

During the proof of concept all RFID readers are of a fixed type; once this technology
has been proven, the treatment facility will use hand held readers
© 2008 TASC / Tech4Care Intro sheet # TfC/07/020009
Process lay out
Manufacturing plant Treament facilities

TAG on infuse
infuse read

Approval by on
attached to on container on duty medication
Define Production Drugs put in Acceptance Treatment
Prescription of drugs* transport RFID by in house ward
container TAG on Pharmacy

Non-RFID data exchange. Transport of Patient

RFID data exchange
container dossier
Physical movement of goods, documents etc.

© 2008 TASC / Tech4Care Intro sheet # TfC/07/0200010

Tech4Care® results*
 Structural decrease of process failures due to human errors by
30 to 60 %
 Improvement of patient’s safety experience
 Reduction of administrative effort of nurses, doctors and
pharmacists by 40 to 60%
 Continuous insight in quality, location and use of high risk
drugs (cytostatics)
 Significant reduction of produced and non-used drugs

* based upon extensive field experiments in Jeroen Bosch Hospital at Den Bosch, Netherlands 2008

© 2008 TASC / Tech4Care Intro sheet # TfC/07/0200011

Additional Information
Herman Timmermans, product manager
TASC Management BV
Westeind 5, 5245 NL Rosmalen
PO Box 77, 5240 AB Rosmalen
The Netherlands
Phone : +31 73 5280030
Fax : +31 73 5280033
Internet :

© 2008 TASC / Tech4Care Intro sheet # TfC/07/0200012